170 related articles for article (PubMed ID: 17234742)
1. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
van Bergen CA; Kester MG; Jedema I; Heemskerk MH; van Luxemburg-Heijs SA; Kloosterboer FM; Marijt WA; de Ru AH; Schaafsma MR; Willemze R; van Veelen PA; Falkenburg JH
Blood; 2007 May; 109(9):4089-96. PubMed ID: 17234742
[TBL] [Abstract][Full Text] [Related]
2. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
3. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
5. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
6. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
7. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
[TBL] [Abstract][Full Text] [Related]
8. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
9. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
[TBL] [Abstract][Full Text] [Related]
10. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
Chao NJ
Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
[TBL] [Abstract][Full Text] [Related]
11. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
[TBL] [Abstract][Full Text] [Related]
12. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
13. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
[TBL] [Abstract][Full Text] [Related]
14. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; van Egmond HM; Willemze R; Falkenburg JH
Blood; 2005 Dec; 106(12):3955-7. PubMed ID: 16099884
[TBL] [Abstract][Full Text] [Related]
15. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
16. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
17. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
19. Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity.
van der Zouwen B; Kruisselbrink AB; Jordanova ES; Rutten CE; von dem Borne PA; Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1353-67. PubMed ID: 22796533
[TBL] [Abstract][Full Text] [Related]
20. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]